| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b1463410dd56d76bf2734343d75b336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dad3284e3e267150b35c37be4f2cb5ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e223dfcf8f6dc4bf11c984b7926a09e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a632dc0950c2a86c1516909a92a0932
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47f079fed01315e7f0429c70e359a9b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d1e6ba1285d3992f4024570f5bc1ff5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate |
2005-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7592b3967c12a8a1e11097d2ecf28e88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_143a97fc1f0bfc704d5d0e189188a45e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b833a78c82caed0ce1bbb28b429cfce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_932b0268b3bafe827e17d049b6264572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0390f911ca1f1348bd840eb0a0d92c3b |
| publicationDate |
2007-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006064321-A3 |
| titleOfInvention |
Controlled release compositions of divalproex sodium |
| abstract |
The present invention pertains to a hydrophilic matrix tablet suitable for the once-a-day administration of valproate compounds such as divalproex sodium. The tablet comprises from about 10 weight percent to about 90 weight percent of an active ingredient selected from the group consisting of valproic acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, and valpromide; from about 6 weight percent to about 18 weight percent of a pharmaceutically acceptable hydrophilic polymer, from about 0.2 weight percent to about 9.5 weight percent of a lubricant, and from about 3 weight percent to about 15 weight percent of a filler; all weight percentages based upon the total weight of the tablet dosage form. Other aspects of the invention relate to the use of this formulation in the treatment of epilepsy and to methods for manufacturing this dosage form. |
| priorityDate |
2004-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |